April 11, 2018
Concussions and CTE have questions swirling about the future of football. This spring, former NFL players are issuing a call to action.
About Exosome Sciences, Inc.
At Exosome Sciences, we are working in collaboration with our majority shareholder, Aethlon Medical (Nasdaq:AEMD), to discover exosome-based biomarkers to diagnose and monitor Alzheimer's disease (AD), Chronic Traumatic Encephalopathy (CTE) and other neurological disorders. We are advancing a TauSome™ biomarker (also referred to as exosomal tau) as the basis for a candidate blood test to diagnose CTE in living individuals. In a recent a recent study, we observed TauSome levels to be significantly elevated in former NFL players as compared to same-age control subjects. High TauSome levels also correlated with poor performance in tests to evaluate cognitive decline. The preliminary results of the study were published in the Journal of Alzheimer’s Disease. We are now planning to establish a follow-on clinical collaboration with up to 200 former NFL football players and clinical investigators at multiple U.S. site locations. If fully enrolled, the study would be the largest to date in former professional football players, who are at a high risk of suffering from CTE.
TauSome™ detection and the use of a TauSome™ biomarker to identify and monitor CTE and other neurological disorders are protected by multiple patent applications.
About Us